Table 3.
Proteasome inhibitor related cardiac adverse events
| Cardiac adverse event, n | Bortezomib (n = 44) | Carfilzomib (n = 52) | Total (n = 96) |
|---|---|---|---|
| Any typea | 7 | 14 | 21 |
| Heart failure | 6 | 7 | 13 |
| Grade 3 or 4 | 3 | 4 | 7 |
| Systemic hypertension | 1 | 3 | 4 |
| Grade 3 or 4 | 1 | 3 | 4 |
| Thromboembolism | 1 | 2 | 3 |
| Grade 3 or 4 | 0 | 0 | 0 |
| Acute coronary syndrome | 1 | 1 | 2 |
| Grade 3 or 4 | 1 | 0 | 1 |
| Atrial fibrillation/flutter | 0 | 2 | 2 |
| Grade 3 or 4 | 0 | 1 | 1 |
| Pulmonary hypertension | 0 | 1 | 1 |
| Grade 3 or 4 | 0 | 1 | 1 |
| Orthostatic hypotension | 0 | 0 | 0 |
| Sudden cardiac death | 0 | 0 | 0 |
aSome patients had multiple events